Application of dopamine receptor antagonist inhibiting WNT-YAP/TAZ pathway for colon cancer treatment
| Project/Area Number |
16K18457
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
Oku Yusuke 岩手医科大学, 薬学部, 講師 (50626843)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | YAP/TAZ / がん分子標的薬 / WNT/beta-catenin / 既存医薬品 / 癌 / シグナル伝達 / 薬学 |
|---|
| Outline of Final Research Achievements |
We originally identified WNT-beta catenin signal inhibitors including pimozide, a dopamine receptor antagonist. In this study, we found that these WNT-beta catenin inhibitors inhibits the nuclear translocation of transcriptional co-activator YAP/TAZ by WNT. Nuclear translocation of YAP/TAZ is facilitated by lysophosphatidic acid (LAP).However, WNT-beta catenin inhibitors including pimozide did not inihbit LAP-mediated nuclear translocation of YAP/TAZ. These results suggested that WNT-beta-catenin inhibitors which we identified preferentially inhibits WNT-mediated nuclear translocation of YAP/TAZ.
|
Report
(3 results)
Research Products
(12 results)
